Loss of response to long-term infliximab therapy in children with Crohn's disease

Oliver Gouldthorpe, Anthony Catto-Smith, George Alex, Dianne M Simpson

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.
Original languageEnglish
Pages (from-to)1322 - 1334
Number of pages13
JournalPharmaceuticals
Volume6
DOIs
Publication statusPublished - 2013

Cite this